Physician profile
William J Ferges
NPI 1982909040
$6,854.27
in general payments reported to CMS, 2019-2025
30 companies · $1,674 in 2025
The $1,674 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $268 · 2021: $995 · 2022: $977 · 2023: $757 · 2024: $1,315 · 2025: $1,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,688 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00 · Education: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,688.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
| Education | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,279.11 | 2019-2025 | |
| Janssen Biotech, INC. | $788.96 | 2019-2025 | Tremfya, Stelara |
| Ironwood Pharmaceuticals, INC | $538.65 | 2019-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $490.90 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $476.87 | 2019-2025 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $298.37 | 2019-2025 | Suflave, Sutab |
| Pfizer INC. | $297.07 | 2019-2025 | |
| Lilly USA, LLC | $202.52 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $192.61 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $176.73 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $138.02 | 2024-2025 | Voquezna |
| Celgene Corporation | $122.63 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $118.84 | 2021-2025 | Rebyota |
| Allergan, INC. | $104.61 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $103.83 | 2024-2025 | Zenpep |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $98.36 | 2019-2022 | |
| Celltrion USA INC. | $68.47 | 2024-2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $45.10 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $44.97 | 2021 | |
| Organon LLC | $43.86 | 2023 | Renflexis, Hadlima |
| Nestle Healthcare Nutrition INC. | $42.95 | 2021-2023 | |
| Genzyme Corporation | $36.03 | 2022-2024 | |
| Echosens North America, INC. | $33.43 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.70 | 2024 | |
| Madrigal Pharmaceuticals | $19.73 | 2024 | Resmetirom |
| Novo Nordisk INC | $17.82 | 2025 | Wegovy |
| Capsovision, INC. | $13.92 | 2023 | Capsocam Plus |
| Alfasigma USA, INC. | $13.86 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.03 | 2019 | |
| Mauna Kea Technologies, INC. | $12.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ferges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.